Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C

Trial Profile

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs TAK-164 (Primary)
  • Indications Colorectal cancer; Gastrointestinal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Nov 2018 Planned End Date changed from 29 May 2022 to 29 Apr 2022.
    • 07 Nov 2018 Planned primary completion date changed from 29 May 2022 to 29 Apr 2022.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top